Health · 4 views
Tau Therapy Shows Continued Benefit at 2 Years in Alzheimer's
Story intelligence
Coverage Single outlet Single-outlet story
Views 4 Community interest
Brief read Under 1 min brief 31 words
Summary
(MedPage Today) -- Diranersen, an investigational antisense oligonucleotide therapy that targets tau, continued to show benefits for 96 weeks, data from the open-label extension of the phase II CELIA trial suggested.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- No clear benefit from two drugs intended to increase spontaneous birth after induction in first-time momsContinue reading
- Creatine supplement use nearly doubles among US college students, new study findsContinue reading
- Brepocitinib yields improvements in cutaneous sarcoidosisContinue reading
- Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trialContinue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow